Diagnostic error: Types and causes

ANNE M. MENKE, RN, PhD, OMIC Risk Manager

In September 2014, the ophthalmologists who compose OMIC’s Claims Committee noticed an increase in OMIC malpractice cases alleging diagnostic error and asked risk management staff to explore the reasons behind this apparent trend. We looked at OMIC claims that were resolved over the seven-year period from 2008 to 2014 and presented this data at the OMIC Forum at the 2015 AAO annual meeting in Las Vegas. Many of our policyholders were not able to attend the Forum, so we are pleased to share this information from the “OMIC study” in the Digest.

The prevalence of diagnostic error has been estimated to range from 10 to 15% of patients in one study and 7 to 17% of patients in another. Studies have found that diagnostic error was the most common cause of claims payments, and that diagnostic error claims were the most expensive and most harmful to patients. Another study reviewed claims in a data sharing project and found that 20% of all claims involved an allegation of diagnostic error, accounting for 35% of claims payments. The PIAA, a trade group whose members provide medical professional liability insurance, found that diagnostic error was the most frequent cause of member reported claims between 2004 and 2013 with the highest average indemnity payment. In the PIAA study of only ophthalmology-related claims since 2004, diagnostic error was the third most frequent allegation against ophthalmologists. Payments were made in 38% of these ophthalmology-related diagnostic error claims.

OMIC claims alleging diagnostic error
We found a smaller percentage of diagnostic error claims in the OMIC study compared with the other studies discussed above. Of the 1613 claims reviewed, 223 alleged a diagnostic error, accounting for 14% of the claims. We paid indemnity on a lower percentage of diagnostic error claims (28%), but these payments account for a similar percentage (34%) of total money paid to settle claims. When compared to all OMIC claims during the period, claims based on allegations of diagnostic error resulted in more paid claims, a higher median and mean payment, and the highest payment (Table 1). Of these diagnostic error claims, cornea claims had the highest percentage settled, while retina claims were the most frequent, had the highest number settled, and the highest total amount paid (Tables 2 and 3). Endophthalmitis diagnostic error claims are costly to settle; the lowest amount paid for these claims was $145,000. But oncology claims stand out as the top diagnostic error payment as well as the highest mean and median payments. There were no paid claims for diagnostic error in neuro, orbit, or uveitis.

MESSAGE FROM THE CHAIR

GEORGE A. WILLIAMS, MD, OMIC Board of Directors

This marks the 100th issue of the Ophthalmic Risk Management Digest for OMIC insureds and presents an opportunity to discuss the history, present status, and future of your medical liability insurance company. It is my great privilege and pleasure to become the eighth Chair of the Board of our remarkable company. To paraphrase Sir Isaac Newton, “We stand on the shoulders of giants.” One of those giants is Tamara Fountain, MD, my immediate predecessor, who completed 15 years of dedicated and impactful service to OMIC as a committee member, board member, executive committee member, and finally as Chair. Tamara’s wisdom, insight, and wit will be missed by the entire OMIC family.

The genesis of OMIC occurred during the medical malpractice liability crisis of the late 1980s. Many ophthalmologists were unable to obtain adequate or affordable coverage. In 1987, the American Academy of Ophthalmology under the visionary leadership of Bruce Spivey, MD, responded to this crisis by creating OMIC as an independent medical liability mutual company under the related claims (not including OMIC’s claims) since 2004, diagnostic error was the third most frequent allegation against ophthalmologists. Payments were made in 38% of these ophthalmology-related diagnostic error claims.

OMIC claims alleging diagnostic error
We found a smaller percentage of diagnostic error claims in the OMIC study compared with the other studies discussed above. Of the 1613 claims reviewed, 223 alleged a diagnostic error, accounting for 14% of the claims. We paid indemnity on a lower percentage of diagnostic error claims (28%), but these payments account for a similar percentage (34%) of total money paid to settle claims. When compared to all OMIC claims during the period, claims based on allegations of diagnostic error resulted in more paid claims, a higher median and mean payment, and the highest payment (Table 1). Of these diagnostic error claims, cornea claims had the highest percentage settled, while retina claims were the most frequent, had the highest number settled, and the highest total amount paid (Tables 2 and 3). Endophthalmitis diagnostic error claims are costly to settle; the lowest amount paid for these claims was $145,000. But oncology claims stand out as the top diagnostic error payment as well as the highest mean and median payments. There were no paid claims for diagnostic error in neuro, orbit, or uveitis.
New society partnerships provide benefits for more ophthalmologists

The Ophthalmic Risk Management Digest is published quarterly by the Ophthalmic Mutual Insurance Company, a Risk Retention Group sponsored by the American Academy of Ophthalmology, for OMIC insureds and others affiliated with OMIC.

OMIC, not the Academy, is solely responsible for all insurance and business decisions, including coverage, underwriting, claims, and defense decisions.

OMIC owns the copyright for all material published in the Digest (except as otherwise indicated). Contact OMIC for permission to distribute or republish any Digest articles or information. The general information on medical and legal issues that OMIC provides in the Digest is intended for educational purposes only and should not be relied upon as a source for legal advice. OMIC will not be liable for damages arising out of the use of or reliance on information published in the Digest.

During the past year, we’ve entered into educational partnerships with three new societies: the Wisconsin Academy of Ophthalmology, the Oregon Academy of Ophthalmology, and the Vit-Buckle Society.

OMIC maintains alliances with most ophthalmic state, subspecialty, and special interest societies in the United States. The Vit-Buckle Society is our 52nd partner organization. Through these cooperative agreements we share patient safety and risk management information and support local lobbying and tort reform efforts.

Policyholders who are members of partner societies earn a 10% risk management discount (an average premium credit of $800) when they complete an approved OMIC risk management event. Since 2000, OMIC has distributed more than $17 million in special premium discounts through this program.

Participate and save on your premium
1. Join (or maintain) state, subspecialty, or special interest partner society membership. (Go to omic.com/partners to see our current list.)
2. Participate in one jointly sponsored OMIC risk management activity per year. For some partners, a jointly sponsored event is any OMIC risk management activity, including a live seminar, audioconference, webinar, or online course.

OMIC generally awards a credit of 5% for risk management activities; however, you may qualify for a 10% discount as an active member of an OMIC partner society. We will honor the credit for approved activities non-OMIC physicians complete within one year of joining OMIC.

If you believe you have not received credit for completing an OMIC-sponsored risk management course, event, or activity, speak with your underwriter. For contact information or to identify your representative, visit omic.com/policyholder-services/contact-my-rep/underwriting.

MESSAGE FROM THE CHAIR continued from page 1

structure of a risk retention group. The founding principle was and remains that OMIC is run by ophthalmologists for ophthalmologists. This principle is the primary driver of our continuing success. No insurer knows ophthalmology better than we do.

At the time the first Digest was published in Winter 1991, OMIC covered 1,064 policyholders across 40 states with $5 million of surplus, written premium of $7 million, and total assets of $20 million. That same year, OMIC distributed a $250,000 dividend to current insureds but still required new insureds to pay a surplus contribution beyond the policy premium.

What a difference 25 years can make! Today, OMIC insures 4,692 ophthalmologists and writes insurance in all 50 states. We have surplus of $193 million and assets of $275 million. Over the past three years, OMIC has returned more than $25 million in dividends to policyholders. For 2016, premiums were cut an average of 12.8% while still paying a 20% dividend.

Today, OMIC carries an A.M. Best rating of A and consistently and substantially outperforms its peer group in frequency and severity of liability claims and payments. This financial strength provides OMIC with new opportunities to become an even more effective advocate and protector for our insureds, our profession, and most importantly, our patients.

In future editions of the Digest, I will discuss OMIC’s continuing legacy of improving patient safety through risk management. Our risk experience provides a unique perspective on how we can minimize clinical errors and improve patient care. That is more than just good business. As a company of ophthalmologists, for ophthalmologists, it is our raison d’être.
MIC's staff, Underwriting Committee, and Board of Directors are continually reviewing OMIC's policy to provide the broadest coverage possible while protecting the company and its owner-insureds from unreasonable risk. In its latest review, the Board determined that OMIC is in the position to safely remove certain exclusions to cover more for our insureds and the work they do. The following summary explains several of the coverage expansions made to the OMIC professional and limited office premises liability policy effective January 1, 2016.

Refractive surgery
The OMIC policy contains a “special procedures” exclusion that, until the January 1, 2016, edition, excluded coverage for any claims arising out of the performance of refractive surgery unless specifically covered by endorsement. To qualify for coverage, the physician had to complete a procedure-specific supplemental questionnaire, undergo special underwriting review, and adhere to specific underwriting requirements. Upon approval, the policy was endorsed to include coverage for the underwritten procedure. This application and approval/endorsement process applied to each type of refractive surgery procedure the physician performed.

The OMIC Underwriting Committee and Board of Directors reviewed this process. Recognizing that refractive surgery has become an integral part of residency training at most institutions, that refractive procedures have become more mainstream in ophthalmology, and that OMIC’s claims trends indicate detailed underwriting of such procedures is not necessary, OMIC will only exclude, and require applications and endorsement for coverage of, intraocular refractive surgery procedures (e.g., phakic implants for refractive purposes and refractive lens exchange). Extraocular refractive surgery procedures, such as LASIK, PRK, and CK, are now automatically covered.

Oculofacial plastic surgery
On the advice of oculofacial plastic surgeons who serve on OMIC’s Board and Committees, the Board reviewed and modified various oculofacial plastic surgery exclusions. They determined that several excluded or conditionally covered procedures were routinely performed by fellowship-trained oculofacial plastic surgeons and that some of the excluded activities were less risky than other permitted procedures. The claims data also indicated that coverage of these procedures would not substantially increase OMIC’s risk. The Board determined that certain “special procedures” no longer need to be excluded from coverage, specifically harvest of a rib graft and placement of arch bars on teeth. The Board also determined that septoplasty could be included under rhinoplasty, and that genioplasty, mentoplasty, and chin implants could be included under full facelifts for cosmetic purposes. This means that if an insured applies for coverage of rhinoplasty and is approved, septoplasty will also automatically be covered; likewise the various procedures under full facelifts for cosmetic purposes.

The Board also determined that the exclusion of certain procedures “not to treat eye conditions and/or diseases,” specifically endoscopic sinus surgery, facial reanimation, harvest of a bone graft, and harvest of ear cartilage are no longer necessary. Therefore, it was removed in its entirety from the policy. A hard copy of the policy is sent to insureds upon renewal. For an electronic copy of the policy, sign into MyOMIC at omic.com. Select “Coverage Q&A and Benefits,” then “Insurance Documents.”

Postoperative care
Until its 2016 revision, OMIC’s policy contained an exclusion denying coverage for claims arising from incidents occurring postoperatively unless specified conditions concerning who performed the postoperative care were satisfied. Since OMIC reviews applicants’ comanagement practices during the underwriting process, the Board determined that this was sufficient to manage the risk and that the postoperative care exclusion was no longer necessary. Therefore, it was removed in its entirety from the policy.

A hard copy of the policy is sent to insureds upon renewal. For an electronic copy of the policy, sign into MyOMIC at omic.com. Select “Coverage Q&A and Benefits,” then “Insurance Documents.”
Diagnostic error: Types and causes

continued from page 1

Clinical categories of OMIC diagnostic error claims
When we look at the clinical categories of diagnostic error claims, retina claims far exceed all other types in both number and percentage of claims (Table 4). Glaucoma, medical, oncology, and cornea claims each represent 12% of these claims. Since ophthalmologists have many questions about endophthalmitis prophylaxis and patients tend to have poor outcomes, we made this a separate category. We will now briefly examine the clinical categories, in descending order of frequency. The table gives both the number of patients and claims. This is because the plaintiff (patient) may sue more than one physician (e.g., both the comprehensive ophthalmologist and the retina specialist) as well as a group practice or surgery center.

2. OMIC DIAGNOSTIC ERROR INDEMNITY PAYMENT ANALYSIS (PART 1)

<table>
<thead>
<tr>
<th>Clinical Category</th>
<th>Patients/Claims</th>
<th>Settled %</th>
<th>Payment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cataract</td>
<td>3/3</td>
<td>1/33</td>
<td>$250,000</td>
</tr>
<tr>
<td>Cornea</td>
<td>18/26</td>
<td>11/44</td>
<td>$1,480,943</td>
</tr>
<tr>
<td>Endophthalmitis</td>
<td>11/17</td>
<td>4/24</td>
<td>$1,610,000</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>24/27</td>
<td>10/37</td>
<td>$1,628,806</td>
</tr>
<tr>
<td>Medical</td>
<td>21/27</td>
<td>10/37</td>
<td>$3,529,000</td>
</tr>
<tr>
<td>Neuro</td>
<td>5/7</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Orbit</td>
<td>2/3</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td>17/27</td>
<td>7/26</td>
<td>$5,341,500</td>
</tr>
<tr>
<td>Retina</td>
<td>57/84</td>
<td>21/25</td>
<td>$7,457,900</td>
</tr>
<tr>
<td>Uveitis</td>
<td>1/2</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

Retina claims. 84 retina claims account for 38% of all OMIC diagnostic error claims during this seven-year period. By far, the most frequently missed diagnosis in our entire study was retinal detachment (RD). These 65 RD claims represent 79% of the retina claims and 48% of the retina payments. The next issue of the Digest will explore these RD claims in detail. While there were only six claims for failure to diagnose retinopathy of prematurity (ROP), these claims compose 47% of the retina payments. There were three age-related macular degeneration claims. The remaining nine claims alleged failure to diagnose retinitis, bilateral acute retinal necrosis (BARN), branch retinal artery occlusion (BRAO), foreign bodies, and a macular hole.

Glaucoma claims. There were 27 claims alleging failure to diagnose glaucoma. Types of glaucoma include primary open angle glaucoma (11 claims, 5 payments), steroid-induced glaucoma (7 claims, 3 payments), narrow angle glaucoma (6 claims, 2 payments), and miscellaneous types (iridocorneal endothelial syndrome or ICE, neovascular, and phacolytic, all of which closed without a payment).

Medical (systemic illness) claims. There were 27 claims where a systemic illness presented with ophthalmic signs and symptoms. The most common of the medical conditions was giant cell arteritis or GCA (11 claims, 6 payments). We addressed these GCA claims in detail in the Digest last year (V25, N3 at omic.com in the Publications section). Systemic infections accounted for seven claims and one payment. Types included subacute bacterial endocarditis and sepsis. Although endogenous endophthalmitis is a systemic condition, we assigned those six claims to the endophthalmitis category. Failure to diagnose a cerebral vascular accident was alleged in five claims, and resulted in three payments.

Oncology claims. There were 27 claims. Failure to diagnose melanoma resulted in six claims and two payments. Pituitary tumors were allegedly missed in four claims but no payments were made. A delay in diagnosing glioma led to three claims and two payments, including a settlement of $2,000,000, the largest one in the study. There were three lacrimal cancer claims with one payment, three optic nerve tumors with no payments, and one trigeminal schwannoma claim, which settled for $1,000,000. We will explore the reasons for these expensive oncology claims and how to prevent them in an issue of the Digest later this year.

Cornea claims. Of the 26 claims, 17 alleged failure to diagnose an infection, leading to six payments. Please see the Closed Claim Study in this issue for a discussion of the challenges in correctly identifying the cause of a corneal infection. There were four keratoconus claims with two payments and four corneal ulcer claims with three payments. This category had the highest percentage of paid claims.

Endophthalmitis claims. There were 17 claims. In six claims, the patient had endogenous endophthalmitis, resulting in three

3. OMIC DIAGNOSTIC ERROR INDEMNITY PAYMENT ANALYSIS (PART 2)

<table>
<thead>
<tr>
<th>Clinical Category</th>
<th>Low</th>
<th>High</th>
<th>Mean (average)</th>
<th>Median (middle)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cataract</td>
<td>$27,500</td>
<td>$588,443</td>
<td>$135,430</td>
<td>$70,000</td>
</tr>
<tr>
<td>Cornea</td>
<td>$145,000</td>
<td>$1,000,000</td>
<td>$402,500</td>
<td>$232,500</td>
</tr>
<tr>
<td>Endophthalmitis</td>
<td>$10,000</td>
<td>$500,000</td>
<td>$139,359</td>
<td>$96,250</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>$100,000</td>
<td>$900,000</td>
<td>$352,900</td>
<td>$325,000</td>
</tr>
<tr>
<td>Medical</td>
<td>$49,999</td>
<td>$2,000,000</td>
<td>$763,071</td>
<td>$850,000</td>
</tr>
<tr>
<td>Retina</td>
<td>$1,650</td>
<td>$1,500,000</td>
<td>$355,138</td>
<td>$187,500</td>
</tr>
</tbody>
</table>
payments. The other cases occurred following trauma (five claims, three payments), cataract surgery (three claims, no payments), and other conditions (one each in a drug user and following pterygium and strabismus surgery, none of which resulted in payments).

and that results of some tests were misinterpreted. They also reported that ophthalmologists often had poor recognition of a worsening or non-responsive condition, and accordingly, did not obtain a second opinion or refer to a specialist in a timely fashion.

Factors impacting the diagnostic process
The diagnostic process is complex, impacted by many factors. These are often divided into three categories: physician (knowledge, skill, etc.), patient (condition and behavior), and system (appointment scheduling process; regulations; insurance rules; drug manufacture, ordering, and administration, etc.). We analyzed factors in claims where the experts felt that the standard of care was not met. The results are shown in Table 6. Physician factors impacted 71 out of 82 claims (87%), patients had no impact, and system issues figured in 11 claims (13%). Please see the Hotline for recommendations on addressing the physician’s role in the diagnostic process.

Our study of 223 diagnostic errors during a seven-year period validated the concerns raised by our Claims Committee. While we present some recommendations on how to reduce these claims in this issue’s Hotline, it is clear that there is no quick or easy solution. Dr. George Williams, OMIC’s new Board Chair, recently informed us that his focus during his tenure will be patient safety, including the risk posed by diagnostic error. We will continue to study diagnostic error in the Digest this year and in presentations we give at state society and subspecialty meetings.

Standard of care evaluation of diagnostic error
As part of the investigation of a claim, both plaintiff and defense attorneys hire experts to review the medical records and allegations in order to determine if the standard of care (SOC) was met. To help us indentify areas of concern, we compared the SOC analysis provided by defense experts (Table 5). Of the 223 claims, 194 were reviewed by defense experts. OMIC-insured ophthalmologists were deemed to have met the standard of care in 112 claims (58%). The standard of care was not met or reviews were mixed (considered together as negative reviews) in 82 (42%) of the claims. While some categories had too few claims to draw any conclusions, we are concerned about the rate of negative reviews in oncology, glaucoma, medical, retina, cornea, and endophthalmitis. Our experts noted that the conditions that were improperly diagnosed were rarely exotic or unusual. They found that the evaluation was often inadequate (insufficient history, exam, or testing).

6. FACTOR ANALYSIS OF OMIC BELOW STANDARD OF CARE (SOC) CLAIMS

5. STANDARD OF CARE (SOC) ANALYSIS OF OMIC CLAIMS WITH EXPERT REVIEWS

<table>
<thead>
<tr>
<th>Clinical Category</th>
<th>Met SOC</th>
<th>Below SOC</th>
<th>Mixed Review</th>
<th>% Negative (Below/Mixed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cataract</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>66</td>
</tr>
<tr>
<td>Cornea</td>
<td>14</td>
<td>3</td>
<td>7</td>
<td>39</td>
</tr>
<tr>
<td>Endophthalmitis</td>
<td>10</td>
<td>2</td>
<td>4</td>
<td>38</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>11</td>
<td>6</td>
<td>3</td>
<td>45</td>
</tr>
<tr>
<td>Medical</td>
<td>12</td>
<td>5</td>
<td>5</td>
<td>45</td>
</tr>
<tr>
<td>Neuro</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Orbit</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>33</td>
</tr>
<tr>
<td>Oncology</td>
<td>12</td>
<td>9</td>
<td>5</td>
<td>54</td>
</tr>
<tr>
<td>Retina</td>
<td>42</td>
<td>20</td>
<td>10</td>
<td>42</td>
</tr>
<tr>
<td>Uveitis</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
A n OMIC-insured general ophthalmologist initially examined the patient for dendrite-appearing lesions on the left eye. The patient had been on Acyclovir and Viroptic, antiviral medications, for two weeks. Upon examination, the insured diagnosed antiviral toxicity with underlying stromal involvement. Lotemax, a steroid eye drop, was prescribed. The insured planned to taper the Viroptic. Upon examination, two days later, the lesion was unchanged. Five days later, the insured noted a raised area of the epithelium that had a dendritic pattern. The area did not stain, so he concluded that this was not an active dendrite. Three days later, the insured noted that the epithelium had broken down and that part of the epithelial surface was missing. The epithelial defect was 6 mm by 2.5 mm with a 1% hypopyon. The ophthalmologist obtained cultures and increased the frequency of the Lotemax and decreased the frequency of the Viroptic. Cultures revealed no white blood cells or organisms on the gram stain, no growth on the general culture, and no virus in the tissue biopsy. There were inadequate cells for antigen detection in the adenovirus and herpes simplex stains. Due to the progression of the patient’s condition, he referred her to an OMIC-insured corneal specialist and asked her to inform the specialist that he suspected acanthamoeba. The corneal specialist’s initial impression was a neurotrophic-appearing cornea with a 4 mm defect at the center of the cornea and some small peripheral defects, and Viroptic toxicity. Acyclovir was increased and Viroptic was discontinued. The patient was started on a low dose steroid and 50% serum tears. After the visit with the corneal specialist, the patient self-referred to a non-OMIC insured ophthalmologist, who diagnosed neurotrophic keratoconjunctivitis. The cultures he obtained were all negative. It was only after the referral to the OMIC-insured corneal specialist that a pathologist determined that the patient had acanthamoeba. The general ophthalmologist needed to perform a scraping and plating of the specimen on media that was more likely to grow acanthamoeba. The expert testified that both the general ophthalmologist and corneal specialist should have seen the patient more frequently until her condition improved. Following the enucleation, OMIC’s defense counsel retained a pathologist to examine the specimen; however, they did not proceed with the examination out of concern that the review would confirm the presence of acanthamoeba. Plaintiff counsel did move forward with a pathology expert, and just as defense counsel feared, the pathologist identified acanthamoeba on the slides. The defense’s own pathology expert then confirmed the presence of acanthamoeba. The patient could not be saved, and the defense’s own pathology expert testified that both the general ophthalmologist and corneal specialist should have seen the patient more frequently until her condition improved. Following the enucleation, OMIC’s defense counsel retained a pathologist to examine the specimen; however, they did not proceed with the examination out of concern that the review would confirm the presence of acanthamoeba. The defense’s own pathology expert then confirmed the presence of acanthamoeba. Prior to this development, OMIC spent $500,000 defending the insureds due to a strong belief that the case was defensible. This problematic development changed the defense team’s opinion and a settlement of $210,000 was negotiated on behalf of the general ophthalmologist and his group and the corneal specialist.

Risk management principles

This case illustrates how challenging it can be to correctly diagnose certain types of corneal infections. Cultures were obtained by each physician and all were negative. It was only after an enucleation that a pathologist determined the presence of acanthamoeba. The general ophthalmologist could not make a definitive diagnosis yet waited two weeks to refer the patient to a corneal specialist. The corneal specialist also struggled to pinpoint the cause of the patient’s condition but did not refer the patient to a specialist at the local university for two months. When a diagnosis cannot be reached and a patient continues to deteriorate, it is prudent to promptly refer the patient on to a specialist for further examination and testing. The plaintiff argued that if the referrals had been expedited, treatment could have started earlier and the eye might have been saved.
What can physicians do to improve diagnostic accuracy?

ANNE M. MENKE, RN, PhD, OMIC Risk Manager

When we presented the data from our study of diagnostic error at the 2015 OMIC Forum, we asked the ophthalmologists in the audience to vote on what factor contributed the most to diagnostic errors. The choices were: atypical presentations (patient factors), physician's cognitive process (physician factors), failure to follow up on test results (system issues), or poor communication among healthcare providers (system issues). Most ophthalmologists voted for the two types of system issues. However, when we analyzed factors in claims where the experts felt the standard of care was not met, we found instead that physician factors were the main force driving these claims (87%). System issues figured in only 13% of the claims, and patient factors in none. The correct answer to our audience response question was, therefore, the physician's cognitive process.

Q What do we know about the cognitive process?

A There have been many studies on decision-making in general and a growing number on clinical reasoning. Researchers have identified two different ways we reason called System 1 and 2, or Fast and Slow Thinking.¹ Fast thinking draws upon our experience and is intuitive and automatic, while slow thinking is deliberative and rational. When first learning a new skill, we use mostly slow thinking and then rely upon fast thinking once the skill is mastered. A common example is learning how to drive, which becomes more and more automatic but needs to be deliberative in bad weather.

Q Is fast thinking effective during the diagnostic process?

A Without being able to move expeditiously through the diagnostic process, physicians would have difficulty seeing patients as scheduled. It is reassuring to know that fast thinking works well much of the time. Experts feel that physicians can safely rely upon it when attempting to diagnose patients with common conditions that present in typical, easily recognized ways. The very cognitive shortcuts and biases that make the process so efficient, however, can lead physicians astray. They may quickly arrive at a diagnosis and forego a more extensive exam or review of systems. Or they may rely upon an earlier thorough examination when following patients for a known condition. This happened in a number of glaucoma cases when physicians failed to regularly examine the optic nerve or compare current IOP measurements to earlier ones to check for slow changes over time. Memories of recent similar cases may also adversely influence the decision-making process. One physician in our study who had recently diagnosed giant cell arteritis gave that same diagnosis to a patient who ended up having a retinal detachment.

Q How can I involve patients in the diagnostic process?

A The Institute of Medicine recently published a book-length analysis titled “Improving Diagnosis in Health Care.”² It identified the patient as key to the diagnostic process by defining diagnostic error as “the failure to (a) establish an accurate and timely explanation of the patient’s health problem(s) or (b) communicate that explanation to the patient.” The report made some suggestions. Clarify that arriving at a diagnosis is a process that takes time. Explain to the patient what you think is causing the condition and then ask if your explanation makes sense to the patient. Share uncertainty. This lesson was hard-earned by one physician in our study who did not determine the cause of vision loss. He reported after his lawsuit was settled that he now lets patients know when he has not yet found a cause for the vision loss and makes sure to discuss unexplained vision loss with colleagues.

1. See, for example, Daniel Kahneman. “Thinking: fast and slow.” Farrar, Straus, and Giroux. 2011
OMIC continues its popular risk management program. Upon completion of an OMIC online or PDF course, CD/DVD, or live seminar, OMIC insureds receive one risk management premium discount per premium year to be applied upon renewal. For most programs, a 5% risk management discount is available; however, insureds who are members of a cooperative venture society (indicated by an asterisk) may earn an additional discount by participating in an approved OMIC risk management activity. Contact Linda Nakamura at 800.562.6642, ext. 652, or lnakamura@omic.com, for questions about OMIC’s risk management seminars, CD/DVD recordings, or computer-based courses. Courses are also listed at omic.com.

Webinars (available to OMIC insureds at no charge)
My Doctor Never Told Me That Could Happen!
Telephone Screening: Liability Issues & Guidelines
Using Checklists to Prevent Patient Harm

April
7 Pediatric Malpractice Claims Alleging Failure to Diagnose. American Association for Pediatric Ophthalmology & Strabismus.* Vancouver Convention Center, Vancouver, BC; 2:45–4 pm. Contact AAPOS at 415.561.8505 or aapos.org/meeting/2016_annual_meeting.
8 Order in the Court: The Art and Ethics of the Witness Stand and Other Legal Issues in Pediatric Ophthalmology. American Association for Pediatric Ophthalmology & Strabismus.* Vancouver Convention Center, Vancouver, BC; 1:15–2:30 pm. Contact AAPOS at 415.561.8505 or aapos.org/meeting/2016_annual_meeting.

May
1 Medico-Legal Issues of the Electronic Health Record: An Attorney Perspective. West Virginia Academy of Eye Physicians & Surgeons.* The Resort at Glade Springs, Daniels, WV; 1–2 pm. Contact WVAEPS at 304.598.4861 or keeberthsc.wvu.edu.
5 OMIC Update and AAO Federal and State Issues Update. AOCOO-HNS 100th Annual Meeting. The Phoenician, Scottsdale, AZ; 12:15–1 pm and 1–2 pm. Contact the society at 800.455.9404 or aocoohns.org/.
9 Topics in Medical Malpractice: When to Contact Your Insurance Company. ASCRS-ASOA Annual Meeting. Ernest N. Morial Convention Center, New Orleans, LA; 10–11:30 am, Room 242. Contact 703.591.2220 or ascrs@xpressreg.net.
12 OMIC Closed Claims. Massachusetts Society of Eye Physicians & Surgeons.* MMS Headquarters, Waltham, MA; 6–7 pm. Contact MSEPS at 617.426.2020 or mseps.org/.